Sleep Restriction and Metabolism Study

This study is looking at how restricting sleep affects your metabolism, including weight gain, food choices, and how your body handles sugar (glucose tolerance). Researchers want to understand why short sleep might lead to health problems like obesity and diabetes. You would be assigned to a group that either has sleep restriction first or a control period first, and then you'd switch groups. During the study, you'll be provided with three meals a day and can eat other food as desired. The study is looking for 20 healthy volunteers between 18 and 40 years old who do not have dietary restrictions. The study's current status is unclear.

Study design
This is a randomized-crossover study involving 20 participants. You would be assigned to a sleep restriction group or a control group first, then switch to the other group.
What's involved
The study lasts 21 days, with 7 days as an outpatient and 14 days as an inpatient. During this time, your circadian phase, energy intake, and energy content will be measured.
Compensation
Not stated in the trial record.
Follow-up
Measurements for circadian phase, energy intake, and energy content are taken at 14 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05775627

Sleep and Metabolism

Recruiting
NAAges 18–40Interventional
Oregon Health and Science University
~20 participants
Updated 2024-04-03 on ClinicalTrials.gov
What's tested:Sleep Restriction

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Circadian Phase
Measured over 14 days
+25 more outcomes measured
Sleep Deprivation
Obesity
Glucose Intolerance
Weight Gain
Food Selection
1 sites across 1 states
Oregon1
  • Andrew McHill, PhD · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Between 18 and 40 years of age
Drug free
Established disease-free status

Exclusion

Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream) 2. Body Composition
Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician
A history of severe psychiatric illnesses
Alcoholism
Drug dependency
Major depression
Manic depressive illness
Schizophrenic disorders
Panic disorder
Generalized anxiety disorder
Post-traumatic stress disorder
Agoraphobia
Claustrophobia
Paranoid personality disorder
Schizoid personality disorder
Schizotypal personality disorder
Borderline personality disorder
Antisocial personality disorder.
History of using antidepressant medication
History of using neuroleptic medication
History of using tranquilizers 4. Drug/alcohol use
Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking 5. Medication/drug use
Working irregular day and night hours
Regular night work
Rotating shift work f
Not have traveled more than 1 time zone during 3 months prior to the study 7. Chronobiologic and sleep disorders
Hypernychthemeral sleep/wake cycle
Delayed sleep phase syndrome (wake time \> 2 hours later than desired or habitually after 10:00 AM)
Advanced sleep phase syndrome (wake time \> 2 h earlier than desired or habitually before 5:00 AM)
Narcolepsy
Sleep apnea (apnea index \>15)
Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \< 80%)
Hypersomnia
Periodic Limb Movement (PLMS) (PLMS index \>15)
Nocturnal Paroxysmal Dystonia
REM-sleep behavior disorder
Nocturnal Enuresis; (self-report and first night in the laboratory)
Obstructive sleep apnea (apnea/hypopnea index \>5/h as determined by at-home monitoring)
The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness/Eveningness questionnaire (i.e., the Owl/Lark Questionnaire) 8. Diseases of the Cardiovascular System
Hypertension (systolic blood pressure \> 140 or diastolic blood pressure \> 90)
Heart failure
Cardiomyopathy
Cor pulmonale
Ischemic heart disease
Valvular heart disease
History of heart transplantation
Cardiac tumors
Pericardial disease 9. Metabolic Syndrome
HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women
Systolic blood pressure \>135 mmHg or diastolic blood pressure \>85 mmHg
Fasting blood glucose ≥ 100 mg/dL
Triglycerides ≥ 150 mg/dL 10. Pre-Diabetes/Diabetes
Asthma
Cystic fibroses
Chronic bronchitis
Emphysema
Airway obstruction
Interstitial lung diseases
Pulmonary hypertension
Lung neoplasms
ARDS 13. Disorders of the Kidney and Urinary Tract
Acute or chronic renal failure
History of renal transplantation
Tubulointerstitial diseases of the kidney
Urinary tract obstruction
Tumors of the urinary tract 14. Infectious Diseases
Infective endocarditis
HIV infection
Sexually transmitted diseases \[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\],
Urinary tract infection
Osteomyelitis
Brucellosis
Toxoplasmosis,
Tuberculosis
Leptospirosis
Lyme disease
Mononucleosis
Hepatitis
Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis 15. Disorders of the Gastrointestinal System
Esophagitis
Peptic ulcer and gastritis
Neoplasms of the esophagus, stomach or bowel
Disorders of absorption
Inflammatory bowel disease
Diseases of the small and large intestine
Acute appendicitis
Cirrhosis or neoplasms of the liver
History of liver transplantation
Diseases of the gallbladder and bile ducts
Pancreatic disease 16. Disorders of the Immune System, Connective Tissue and Joints
AIDS
Systemic lupus erythematosus
Rheumatoid arthritis
Scleroderma
Ankylosing spondylitis
Vasculitis
Sarcoidosis 17. Disorders of the Hematopoietic System
Anemia
Leukemia
Myeloproliferative diseases
History of bone marrow transplantation 18. Neoplastic Diseases
Lymphoma
Carcinoma
Melanoma
Any other neoplastic diseases 19. Endocrine and Metabolic Diseases
Thyroid disease
Addison's Disease
Cushing's Syndrome
Aldosteronism
Hypoaldosteronism
Pheochromocytoma
Disorders of sexual differentiation that require hormone supplementation that may alter body weight
Disorders of neuroendocrine regulation
Diseases of the anterior pituitary and hypothalamus
Hemochromatosis porphyria
Wilson's Disease
Glycogen storage diseases
Diseases of the parathyroid gland
Metabolic bone disease
Disorders of phosphorus or magnesium metabolism
Paget's Disease 20. Neurologic Disorders
Epilepsy and disorders of consciousness
Dementia
Amnesic disorders
Neoplastic diseases of the central nervous system
Demyelinating diseases
Parkinson's Disease
Muscular dystrophy
Myasthenia gravis
Periodic paralysis
Dermatomyositis
Polymyositis
Infections of the nervous system
Stroke
History of transient ischemic attacks
Hydrocephalus
Tumors of the pituitary gland
Pinealoma
Intervertebral disc disease
Ataxia
Gilles de la Tourette Syndrome
Huntington's Disease
Tardive dyskinesia
History of recurrent migraine headaches
Neuromuscular disease. 21. Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:
Ingest experimental medication
Give blood samples
  • Circadian Phase14 days

    Saliva will be assayed for melatonin used standardized assays. Melatonin will be sampled at 1h intervals during wakefulness. Melatonin onset will be calculated using the linear interpolated time at which melatonin levels reach 25% of a fitted peak-to-trough amplitude.

  • Energy Intake14 days

    Throughout the forced desynchrony protocol, participants will have ad libitum access to food, which will be scored using NDSR software. NDSR was developed to help plan, manage, and analyze food and nutrient intake. Each meal and set of snacks will be timestamped (midpoint of snack availability) and binned by circadian phase based on the individuals' melatonin and also by time awake.

  • Energy Content14 days

    Throughout the forced desynchrony protocol, participants will have ad libitum access to food, which will be scored using NDSR software. NDSR was developed to help plan, manage, and analyze food and nutrient intake. Each meal and set of snacks will be timestamped (midpoint of snack availability) and binned by circadian phase based on the individuals' melatonin and also by time awake.

  • Glucose Metabolism~3 days

    The participant's glucose and insulin response to a mixed meal diet high in carbohydrates may be tested up to 3 times during the protocol (Days 2, 4, and 13). Each participant will have a choice of 1 of 2 meal options and will be given that meal throughout the study. During this mixed meal test, a baseline blood draw will occur \~7-min before the meal and then the frequency of blood samples will increase to every 10-min after the meal for 90 min and then every 30 min for 90 min for a total of 14 samples (\~1 mL each, total of \~14 mL) over 180 minutes to measure glucose and hormone response in detail. Samples at each time point will be obtained for measurement of suppressibility of plasma free fatty acids. Blood will also be drawn every 4h during the protocol for 24h insulin and glucose.

  • Resting energy expenditure14 days

    Resting energy expenditure will be measured upon awaking each protocol day via indirect calorimetry. Oxygen consumption and carbon dioxide production will be used to calculate metabolic rate.

  • Resting energy macronutrient oxidation14 days

    Resting macronutrient oxidation will be measured upon awaking each protocol day via indirect calorimetry. Oxygen consumption and carbon dioxide production will be used to calculate the oxidation of carbohydrate and fat.

  • Blood Pressure14 days

    Beat-to-beat blood pressure will be obtained using a non-invasive device employing the volume-clamp method with hydrostatic correction (Nexfin). Beat-to-beat blood pressure will be recorded 1) during each sleep episode and 2) each constant posture period following awakening. Both systolic and diastolic blood pressure will be measured.

  • Heart Rate14 days

    For the duration of the study, 2 channels of EKG are recorded (RA-V6) and stored on BioPac recorders using Acqknowledge software (256 Hz).

  • Sympathetic Activity14 days

    The investigators will use the high frequency power of the heart rate variability power spectrum to estimate cardiac parasympathetic activity (vagal tone) as modulated by respiratory sinus arrhythmia. RR interval data for sequential 5-minute time segments will be used for heart rate variability analysis according to published criteria. Frequency domain measures are calculated by interpolating the RR tachogram with a cubic spline and re-sampling. Power spectral density will be calculated using Welch's technique. Calculated time domain heart rate variability measures will include mean RR, SD of all normal-normal RR intervals, and a percentage of RR intervals differing by greater than 50 msec.

  • Parasympathetic Activity14 days

    The investigators will use the high frequency power of the heart rate variability power spectrum to estimate cardiac parasympathetic activity (vagal tone) as modulated by respiratory sinus arrhythmia. RR interval data for sequential 5-minute time segments will be used for heart rate variability analysis according to published criteria. Frequency domain measures are calculated by interpolating the RR tachogram with a cubic spline and re-sampling. Power spectral density will be calculated using Welch's technique. Calculated time domain heart rate variability measures will include mean RR, SD of all normal-normal RR intervals, and a percentage of RR intervals differing by greater than 50 msec.

  • Vascular Endothelial Function14 days

    The investigators will measure vascular endothelial function at various points throughout the protocol. Brachial or femoral artery flow-mediated dilation will be measured in the supine position.

  • Leptin14 days

    The investigators will measure markers of hunger via the satiety hormone leptin. Blood will be assayed using our standard procedures approximately every six hours.

  • Ghrelin14 days

    The investigators will measure markers of hunger via the hunger hormone ghrelin. Blood will be assayed using our standard procedures approximately every six hours.

  • Endocannabinoids14 days

    The endocannabinoids 2-AG and AEA, as well as non-endocannabinoid N-acylethanolamines (N-oleoylethanolamine \[OEA\] and N-palmitoylethanolamine \[PEA\]), and 2-monoacylglycerols (2-oleoylglycerol \[2-OG\]) via blood. Blood will be assayed using our standard procedures approximately every six hours.

  • Posture Test Blood Pressure14 days

    Standing up after a period of lying down is a large physiological challenge requiring sympathetic activation to maintain perfusion pressure to the brain and void syncope. Participants will be fitted with a 2 lead EKG, a finger cuff for non-invasive BP recordings on a beat-by-beat basis and a sphygmomanometer cuff on the other arm for manual assessment of BP \[for cross calibration and safety check\]. The finger cuffs will be placed on the non-dominant hand and held in place by an arm sling so that the BP cuffs will be at heart level. BP will be assessed while participants stand up from a semi-recumbent posture and remain standing for \~5min.

  • Posture Test Heart Rate14 days

    Standing up after a period of lying down is a large physiological challenge requiring sympathetic activation to maintain perfusion pressure to the brain and void syncope. Participants will be fitted with a 2 lead EKG, a finger cuff for non-invasive BP recordings on a beat-by-beat basis and a sphygmomanometer cuff on the other arm for manual assessment of BP \[for cross calibration and safety check\]. The finger cuffs will be placed on the non-dominant hand and held in place by an arm sling so that the BP cuffs will be at heart level. HR will be assessed while participants stand up from a semi-recumbent posture and remain standing for \~5min.

  • External Temperature Assessment14 days

    Skin temperatures (in degrees Celsius) will be continuously assessed using wireless Thermochron iButtons. These iButtons are small (1.6 cm x 0.6 cm), independent temperature sensors and use data loggers enclosed in a watertight stainless-steel package. The iButtons will be taped to the skin with thin, air-permeable adhesive surgical tape in up to 9 different locations and programmed prior to placement via a USB computer interface. Data will be recorded every minute. "Proximal skin temperature" is the averaged skin temperatures of infraclavicular region (mean of left and right) and sternum; "distal skin temperature" is the average skin temperatures of the wrists and ankles.

  • Internal Temperature Assessment14 days

    Temperature data (in degrees Celsius) will also be collected every minute through either rectal thermistors or telemetry pill.The phase of the body temperature rhythm will be determined by the weighted average of the fitted minima of core body temperature data obtained from a single and dual-harmonic fit.

  • Total Energy Expenditure14 days

    Total energy expenditure (TEE) will also be collected across the chronic sleep and circadian disruption protocol by using doubly-labeled water (DLW). DLW is a method based on administration of an oral loading dose of water labeled with both deuterium and oxygen isotope. The tracers quickly equilibrate in the total body water. Deuterium is eliminated from the body in urine only, but the oxygen isotope is eliminated in both urine and carbon dioxide; the difference of the elimination curves is equal to the amount of carbon dioxide expired over the testing period. Urine samples are collected at baseline before the loading dose and again 4-6h after consuming the water on day 1; final urine samples 14 days later.

  • Changes in Alertness14 days

    The investigators will quantify a measure of alertness and hunger to determine the dynamics of acute circadian misalignment and re-entrainment on multiple aspects of waking performance. Alertness will be measured for subjective assessments via a Visual Analog Scale (VAS). The VAS Alert will be performed during sleep inertia testing, which will be the impairment observed immediately upon waking. Sleep inertia testing will occur at \~1, 10, 20, 30, 40, 50, 60, 70, 80, and 90 minutes after waking.

  • Measuring Mood with POMS14 days

    Investigators will measure mood to determine the dynamics of acute circadian misalignment and re-entrainment of waking performance. Mood will be measured by utilizing the POMS questionnaire. The POMS questionnaire is a standard validated psychological test that assesses vigor, fatigue, confusion, anger-hostility, depression, and tension-anxiety by presenting 30 words to participants and requires them to rate how they identify with each word using a numerical value. Each number is associated with a scoring system via a Likert scale (e.g. "Not at All", "A Little", "Moderately", "Quite a Lot" or "Extremely"). These scores are analyzed by a Total Mood Disturbance (TMD) score via the numerical values provided by the participant. Lower scores indicate that a participant has a more consistent or stable mood profile. POMS will be administered beginning two hours after waking and repeated every two hours across wakefulness.

  • Measuring Mood with PANAS14 days

    Mood will be additionally investigated by administering the PANAS questionnaire, which is a self-reported measure and consists of different words that describe emotions. There are two scales to this questionnaire, one which measures a positive affect (the ability for a participant to experience positive emotions or interact positively with others), and a negative affect (experiencing negative emotions or interacting negatively with others). Participants will be presented with a questionnaire with 20 words related to emotions and a 5-point Likert scale. Positive affect scores can range from 10-50, with higher scores representing a higher level of positive affect. Negative affect scores can also range from 10-50, and lower scores represent lower levels of negative affect. PANAS will be administered beginning two hours after waking and repeated every two hours across wakefulness.

  • Changes in Degrees of Sleepiness14 days

    Investigators will use the Stanford Sleepiness Scale (SSS) for a subjective assessment of sleepiness. The SSS uses a 7-point Likert scale in order to quantify sleepiness at the time of test administration. Values are assigned as follows: 1. "Feeling active and vital, alert, or wide awake." 2. "Functioning at a high level, but not at peak; able to concentrate." 3. "Awake, but relaxed; responsive but not fully alert." 4. "Somewhat foggy, let down." 5. "Foggy; losing interest in remaining awake; slowed down." 6. "Sleepy, woozy, fighting sleep; prefer to lie down." 7. "No longer fighting sleep, sleep onset soon; having dream-like thoughts."

  • Changes in Sustained Attention and Reaction Time14 days

    Investigators will administer the Psychomotor Vigilance Task (PVT) is a 10 minute, computer-based test in which the participant presses a button as soon as a light appears on the computer screen. This light will appear randomly every few seconds. The main measurements of this task include the mean and median reaction time in milliseconds and sustained attention, as well as false responses. False responses refers to a participant pressing the button before a light is displayed on the computer screen. Individuals who are sleep deprived or are sleep deficit tend to display decreased alertness, declined psychomotor skills, and increased false responses, and therefore have a slower overall reaction time. This test will be administered starting two hours after waking and repeated every two hours across wakefulness.

  • Changes in Cognitive Performance14 days

    Cognitive performance will be measured by investigators administering the Digit Symbol Substitution Test (DSST). This is a computer test that presents participants with abstract symbols associated with numbers on a computer screen. The participant must match the symbol that appears on the screen with the corresponding abstract symbol and number. The DSST is a 90 second test and results measured include the total correct and participant errors. Higher scores with fewer errors indicate increased cognitive performance. The DSST will be performed during sleep inertia testing, which will be the impairment observed immediately upon waking. Sleep inertia testing will occur at \~1, 10, 20, 30, 40, 50, 60, 70, 80, and 90 minutes after waking.

  • Changes in Working Memory14 days

    The addition (ADD) task is a 2-digit addition task that will be administered via computer test every 2h to assess working memory. Participants are required to answer as many addition questions as they can within a certain time frame. Results measured include the total correct and participant errors. Higher scores with fewer errors indicate an increased ability to hold information temporarily. The ADD task will be administered two hours after waking and repeated every two hours across wakefulness.